We would love to hear your thoughts about our site and services, please take our survey here.
Pharma services business momentum - discussions in progress with more than twenty biopharma companies offering a pipeline of opportunities for new contracts as we move through the end of this year and into 2023. Almost all potential customers are interested in bespoke assay development
· Global sales and distribution network being established with first contracts in negotiation and initial seeding of instruments anticipated
· Accreditation of clinical laboratories in final stages offering ability to offer validated tests for both pharma services and patient management in coming months
· New product roll-out to accelerate with a pipeline of sample-to-answer imaging and molecular solutions being finalised for offer to customers
· Numerous discussions in progress with potential partners including medtech companies, downstream assay providers and clinical laboratories regarding selected Parsortix based assays
I liked this part but also the Ovarian study showing best in class.
These are the standouts,
None of the portfolio companies are yet at the traditional point of exit where value can be maximised.
The reduction in assets under management was also a key driver of a reduction in net asset value per share from 9.2p at 31 December 2021 to 8.5p at 30 June 2022.
No mention at all of the US OTC listing either
No wonder the SP was smashed at outset and down 14%. AS really has to go.
I think the DFS for Vermelho is due to be completed around Q4 2023 when the building of Araguaia, if on timescale, is due to be completed. Of course it would be good to hear news on its progress in the interim also. Especially as JM has stated his belief that there is little chance of us running both mines as a sole company.
I hope Nicole doesn’t mind the quotations included getting her gender wrong. ;-)
Frustrating to see us drift under the £1 level or 5p in old money. It is what it is but I am glad you have finance sorted rather than trying to raise in this market environment. Long term hold for me until production but who knows if something surfaces before.
Well think the RNS has shattered that thought. Going to be a long haul on this one.
As reported on May 31, we submitted an FDA 510(k) application to the USFDA. IB Zero G™ is an automated processing pipeline that leverages patented technology (US Patent No. 11,100,621) to output enhanced post-contrast images using routinely acquired non-contrast images as input. This technology is targeted at the multibillion-dollar global MRI contrast media market offering cost, convenience, and alleviating safety and environmental concerns. The initial 510(k) application followed the Traditional 510(k) pathway. Under this pathway, the sponsoring company identifies a previously FDA cleared "predicate" device and uses the attributes of that predicate device to demonstrate "substantial equivalence" for the new device. The FDA has now determined that the patented artificial intelligence (AI) technology contained in IB Zero G is a novel, a "first in kind", such that no currently cleared device exists that can serve as a predicate to establish substantial equivalence.
In the response, the FDA provided several alternatives including a "de novo" application. The de novo pathway is specifically designed for novel medical devices intended as Class I and Class II (a risk-based classification) and allows the FDA to review new technologies more expeditiously such that patients can have access to safe and effective medical devices sooner. Prior to the establishment of the de novo pathway, novel technologies were automatically considered Class III (highest risk) and underwent a much more rigorous and longer market clearance pathway, called a Premarket Approval (PMA). We do not believe IB Zero G is appropriately considered a Class III device, so IB intends to take advantage of the de novo pathway and will be communicating with the FDA for further clarification and guidance in advance of the de novo submission.
The de novo pathway is simpler and is becoming more frequently used, driven in part by the rapid pace of technology, computing power, and AI algorithmic development.
I have a small position in Thor as they are in varying projects in different jurisdictions. I also think this is interesting also that BHP have had a $8.3bn offer for Oz Metals rejected. Large scale mineral deposits are still in demand especially copper.
https://www.mining.com/hundreds-of-new-mines-required-to-meet-2030-battery-metals-demand-iea-report/
https://events.fastmarkets.com/event/7f3b23bf-96df-4a08-afa1-f9edce4478f4/websitePage:772746ff-5eb3-4de1-b48c-cd0838d78144?_gl=1*ujohqq*_ga*MjExOTE2NjIyLjE2NTAyOTQxMjc.*_ga_SJ8BZV6WD1*MTY1NTEyNTcwNi4xMjIuMS4xNjU1MTI1NzEwLjA.&mmrkt=Energy%20transition
No mention of SAV attending or promoting sadly.